| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0002027 | Regulation of heart rate | Increases phenotype | PMID:2255747; PMID:3157294; PMID:227508; PMID:2322896; PMID:2538899; PMID:7934643; PMID:2996820; PMID:4064558; PMID:8981066 |
| GO:0003094 | Glomerular filtration | Increases phenotype | PMID:3346840 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:33872574 |
| GO:0006171 | Camp biosynthetic process | Increases phenotype | PMID:23300227; PMID:23608241 |
| GO:0006309 | Apoptotic dna fragmentation | Increases phenotype | PMID:12927789; PMID:7848904 |
| GO:0006536 | Glutamate metabolic process | Affects phenotype | PMID:33872574 |
| GO:0006915 | Apoptotic process | Affects phenotype | PMID:10774788; PMID:12015209; PMID:12927789; PMID:12971854; PMID:15345483; PMID:15595686; PMID:15717263; PMID:17465212; PMID:19070643; PMID:20600172; PMID:7848904; PMID:8392561 |
| GO:0006979 | Response to oxidative stress | Increases phenotype | PMID:19070643 |
| GO:0007190 | Activation of adenylate cyclase activity | Decreases phenotype | PMID:6094742 |
| GO:0007268 | Chemical synaptic transmission | Decreases phenotype | PMID:6122334 |
| GO:0008217 | Regulation of blood pressure | Increases phenotype | PMID:11311734; PMID:3157294; PMID:6661468; PMID:11373431; PMID:4052729; PMID:14584016; PMID:227508; PMID:2487544; PMID:2538899; PMID:6745320; PMID:2767128; PMID:2996820; PMID:3059819; PMID:7110629; PMID:33872574; PMID:6274577; PMID:8981066; PMID:9824088 |
| GO:0008219 | Cell death | Increases phenotype | PMID:17542780; PMID:1953803 |
| GO:0008283 | Cell population proliferation | Affects phenotype | PMID:1668613; PMID:17542780 |
| GO:0009408 | Response to heat | Decreases phenotype | PMID:31400342 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:33872574; PMID:8429757 |
| GO:0019226 | Transmission of nerve impulse | Affects phenotype | PMID:6745320 |
| GO:0030595 | Leukocyte chemotaxis | Increases phenotype | PMID:9629232 |
| GO:0033138 | Positive regulation of peptidyl-serine phosphorylation | Affects phenotype | PMID:24398105 |
| GO:0035810 | Positive regulation of urine volume | Increases phenotype | PMID:1356599; PMID:1685782; PMID:2558758; PMID:7110629 |
| GO:0035812 | Renal sodium excretion | Decreases phenotype | PMID:3346840; PMID:3929623 |
| GO:0042116 | Macrophage activation | Increases phenotype | PMID:17084265 |
| GO:0042310 | Vasoconstriction | Affects phenotype | PMID:14751409; PMID:3157294 |
| GO:0042311 | Vasodilation | Affects phenotype | PMID:14751409; PMID:7629406 |
| GO:0042391 | Regulation of membrane potential | Affects phenotype | PMID:21645529; PMID:2850064; PMID:7052335 |
| GO:0042415 | Norepinephrine metabolic process | Affects phenotype | PMID:24398105 |
| GO:0045793 | Positive regulation of cell size | Increases phenotype | PMID:15647486 |
| GO:0048266 | Behavioral response to pain | Decreases phenotype | PMID:31400342 |
| GO:0050901 | Leukocyte tethering or rolling | Decreases phenotype | PMID:10964586 |
| GO:0050965 | Detection of temperature stimulus involved in sensory perception of pain | Decreases phenotype | PMID:25154594; PMID:26791602 |
| GO:0050966 | Detection of mechanical stimulus involved in sensory perception of pain | Decreases phenotype | PMID:26791602 |
| GO:0051461 | Positive regulation of corticotropin secretion | Affects phenotype | PMID:24398105 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Decreases phenotype | PMID:19070643 |
| GO:0060073 | Micturition | Affects phenotype | PMID:2565272 |
| GO:0060079 | Excitatory postsynaptic potential | Increases phenotype | PMID:11164562 |
| GO:0060326 | Cell chemotaxis | Affects phenotype | PMID:11106302; PMID:15647486 |
| GO:0061366 | Behavioral response to chemical pain | Increases phenotype | PMID:30763598 |
| GO:0061367 | Behavioral response to acetic acid induced pain | Decreases phenotype | PMID:29555329 |
| GO:0061368 | Behavioral response to formalin induced pain | Decreases phenotype | PMID:29555329; PMID:31857126 |
| GO:0071316 | Cellular response to nicotine | Affects phenotype | PMID:27068812 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:33872574 |
| GO:0090394 | Negative regulation of excitatory postsynaptic potential | Increases phenotype | PMID:6259338 |
| GO:0097280 | Histamine secretion mediated by immunoglobulin | Increases phenotype | PMID:2471936; PMID:9372312 |
| GO:1904180 | Negative regulation of membrane depolarization | Increases phenotype | PMID:25967872 |
| GO:2000854 | Positive regulation of corticosterone secretion | Affects phenotype | PMID:24398105 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.